Phase II study of interleukin-2 and 13-cis-retinoic acid as maintenance therapy in metastatic colorectal cancer

Cancer Immunology, Immunotherapy

Volumn 56, Issue 5, 2007, Pages 699-708

  Recchia, Francesco ^a,b,g   Saggio, Gaetano ^a   Cesta, Alisia ^a   Candeloro, Giampiero ^a   Di Blasio, Anna ^a   Amiconi, Giovanna ^a   Lombardo, Marco ^c   Nuzzo, Antonio ^d   Lalli, Angelo ^e   Alesse, Edoardo ^f   Necozione, Stefano ^f   Rea, Silvio ^b,f  

^a Ospedale Civile di Avezzano   (Italy)

^b Fondazione Carlo Ferri   (Italy)

^c Ospedale Civile di Pescara   (Italy)

^d Ospedale Civile di Lanciano   (Italy)

^e Ospedale Civile di Giulianova   (Italy)

^f UNIVERSITY OF L'AQUILA   (Italy)

^g NONE   (Italy)

Author keywords

13 cis retinoic acid; Interleukin 2; Lymphocyte; Maintenance therapy; Metastatic colorectal cancer; Natural killer cells

Indexed keywords

FLUOROURACIL; FOLINIC ACID; INTERLEUKIN 2; ISOTRETINOIN; OXALIPLATIN; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; COMPARATIVE STUDY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FEVER; FOLLOW UP; HUMAN; HYPOTHYROIDISM; IMMUNOTHERAPY; LYMPHOCYTE COUNT; MAINTENANCE THERAPY; MALE; NATURAL KILLER CELL; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SIDE EFFECT; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INTERLEUKIN-2; ISOTRETINOIN; KILLER CELLS, NATURAL; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; SURVIVAL ANALYSIS;

EID: 33847389749     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-006-0224-9     Document Type: Article

References (38)

1. Aass N, De Mulder PH, Mickisch GH, Mulders P, van Oosterom AT, van Poppel H, Fossa SD, de Prijck L, Sylvester RJ (2005) Randomized phase II/III trial of interferon alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951). J Clin Oncol 23:4172-4178
2. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A (2004) Multicenter international study of oxaliplatin/5-fluorouracil/leucovorin in the adjuvant treatment of colon cancer (MOSAIC) investigators. N Engl J Med 350:2343-2351
3. Boyle P, Ferlay J (2005) Cancer incidence and mortality in Europe. Ann Oncol 16:481-488
4. Brivio F, Lissoni P, Rovelli F, Nespoli A, Uggeri F, Fumagalli L, Gardani G (2002) Effects of IL-2 preoperative immunotherapy on surgery-induced changes in angiogenic regulation and its prevention of VEGF increase and IL-12 decline. Hepatogastroenterology 49:385-387
5. Cascinu S, Graziano F, Valentini M, Catalano V, Giordani P, Staccioli MP, Rossi C, Baldelli AM, Grianti C, Muretto P, Catalano G (2001) Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: relationships with tumor recurrence and resistance to adjuvant chemotherapy. Ann Oncol 12:239-244
6. Cesana GC, Gail DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, Stoutenburg J, Cheung K, Hesdorffer C, Kim-Schulze S, Kaufman HL (2006) Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 24:1169-1177
7. Correale P, Cusi MG, Tsang KY, Del Vecchio MT, Marsili S, La Placa M, Intrivici C, Equino A, Micheli L, Nencini C, Ferrari F, Giorni G, Bonmassar E, Guido Francini G (2005) Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. J Clin Oncol 23:8950-8958
8. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345
9. Disis ML, Kim Lyerly K (2005) Global role of the immune system in identifying cancer initiation and limiting disease progression. J Clin Oncol 23:8923-8925
10. Fox FE, Kubin M, Cassin M, Niu Z, Trinchieri G, Cooper KD, Rook AH (1999) Retinoids synergize with interleukin-2 to augment IFN-gamma and interleukin-12 production by human peripheral blood mononuclear cells. J Interferon Cytokine Res 19:407-415
11. Fumagalli LA, Vinke J, Hoff W, Ypma E, Brivio F, Nespoli A (2003) Lymphocyte independently predict overall survival in advanced cancer patients: a biomarker for IL-2 immunotherapy. J Immunother 26:394-402
12. Gabrilovich DI, Velders MP, Sotomayor EM, Kast WM (2001) Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol 166:5398-5406
13. Greco FA, Figlin R, York M, Einhorn L, Schilsky R, Marshall EM, Buys SS, Froimtchuk MJ, Schuller J, Schuchter L, Buyse M, Ritter L, Man A, Yap AK (1996) Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. J Clin Oncol 14:2674-2681
14. Hengesbach L, Hoag K (2004) Physiological concentrations of retinoic acid favor myeloid dendritic cell development over granulocyte development in cultures of bone marrow cells from mice. J Nutr 134:2653-2659
15. Herberman RB (1985) Design of clinical trials biological response modifiers. Cancer Treat Rep 69:1161-1164
16. Hill M, Norman A, Cunningham D, Findlay M, Nicolson V, Hill A, Iveson A, Evans C, Joffe J, Nicolson M (1995) Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer J Clin Oncol 13:1287-1290
17. Huang B, Pan PY, Li Q, Sato AI, Levy DE, Bromberg J, Divino CM, Chen SH (2006) Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 66:1123-1131
18. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342
19. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
20. Kosmidis PA, Tsavaris N, Skarlos D, Theocharis D, Samantas E, Pavlidis N, Briassoulis E, Fountzilas G (1996) Fluorouracil and leucovorin with or without interferon alfa-2b in advanced colorectal cancer: analysis of a prospective randomized phase III trial. Hellenic Cooperative Oncology Group. J Clin Oncol 14:2682-2687
21. Kusmartsev S, Cheng F, Yu B, Nefedova Y, Sotomayor E, Lush R, Gabrilovich D (2003) All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res 63:4441-4449
22. Mancuso P, Burlini A, Pruneri G, Goldhirsch A, Martinelli G, Bertolini F (2001) Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 97:3658-3661
23. Maughan TS, James RD, Kerr DJ, Ledermann JA, McArdle C, Seymour MT, Cohen D, Hopwood P, Johnston C, Stephens RJ, British MRC Colorectal Cancer Working Party (2002) Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet 359:1555-1563
24. Motzer RJ, Murphy BA, Bacik J, Schwartz LH, Nanus DM, Mariani T, Loehrer P, Wilding G, Fairclough DL, Cella D, Mazumdar M (2000) Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 18:2972-2980
25. Naumov GN, Bender E, Zurakowski D, Kang SY, Sampson D, Flynn E, Watnick RS, Straume O, Akslen LA, Folkman J, Almog N (2006) A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst 98:316-325
26. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Galon J (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353:2654-2666
27. Recchia F, De Filippis S, Rosselli M, Saggio G, Cesta A, Fumagalli L, Rea S (2001) Phase IB study of subcutaneously administered interleukin-2 in combination with 13-cis retinoic acid as maintenance therapy in advanced cancer. Clin Cancer Res 7:1251-1257
28. Recchia F, De Filippis S, Rosselli M, Saggio G, Fumagalli L, Rea S (2002) Interleukin-2 and 13-cis retinoic acid in the treatment of minimal residual disease: a phase II study. Int J Oncol 20:1275-1282
29. Recchia F, Nuzzo A, Lalli A, Lombardo M, Di Lullo L, Fabiani F, Fanini R, Venturoni L, Torchio P, Peretti G (1996) Randomized trial of 5-fluorouracil and high-dose folinic acid with or without alpha-2b interferon in advanced colorectal cancer. Am J Clin Oncol 19:301-304
30. Recchia F, Rea S, Nuzzo A, Lalli A, Di Lullo L, De Filippis S, Saggio G, Biondi E, Massa E, Mantovani G (2004) Oxaliplatin fractionated over two days with bimonthly leucovorin and 5-fluorouracil in metastatic colorectal cancer. Anticancer Res 24:1935-1940
31. Recchia F, Saggio G, Cesta A, Alesse E, Gallo R, Necozione S, Rea S (2005) Phase II randomized study of interleukin-2 with or without 13-cis retinoic acid as maintenance therapy in patients with advanced cancer responsive to chemotherapy. Anticancer Res 25:3149-3157
32. Recchia F, Saggio G, Nuzzo A, Lalli A, Lullo LD, Cesta A, Rea S (2004) Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX. Br J Cancer 91:1442-1444
33. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE (1989) Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210:474-484
34. Sakaguchi S (2004) Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22:531-562
35. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10
36. Smith KA (1988) Interleukin-2: inception, impact and implications. Science 240:1169-1176
37. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
38. Thomas R, Malek TR, Bayer AL (2004) Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 4:665-674